Garrett Winslow Joins Spring Bank as Vice President of Legal
January 04 2017 - 9:00AM
Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of viral infections, cancer and inflammatory diseases,
today announced that Garrett Winslow, Esq., has been appointed Vice
President of Legal, a newly created role. Mr. Winslow will be a
member of the management team and will be responsible for corporate
legal operations for Spring Bank Pharmaceuticals.
Mr. Winslow brings to the company over 11 years of
experience in the life sciences industry. Prior to joining Spring
Bank, he served as a member in the Corporate and Securities group
at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. in Boston,
Massachusetts, where he advised public and private companies on
securities law compliance, corporate governance matters and mergers
and acquisitions. Mr. Winslow received his Masters in Taxation from
Boston University Law School, J.D. degree from Suffolk University
Law School and B.A. degree in Business Administration from the
University of Washington.
Martin Driscoll, Spring Bank president and chief
executive officer, stated, “I am very pleased to welcome Garrett
Winslow to Spring Bank. Garrett’s experience and expertise will be
important to us as we advance our development and regulatory
activities, continue to pursue new strategic collaborations, and
expand our organizational capabilities at Spring Bank.” Mr.
Driscoll continued, “We look forward to an exciting year in 2017 as
we advance our development programs towards several major
milestones during the year.”
“I am excited about the opportunity to work with
Spring Bank Pharmaceuticals, an emerging biotechnology company that
I believe has significant potential with the company’s
differentiated small molecule nucleic acid hybrid (SMNH) platform,”
said Mr. Winslow. “I look forward to working with the Spring Bank
management team members in the development of our lead compounds,
SB 9200 and SB 11285, as well as enhancing our development efforts
through various strategic partnerships.”
About Spring Bank
Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage
biopharmaceutical company engaged in the discovery and development
of a novel class of therapeutics using its proprietary small
molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH
compounds are small segments of nucleic acids that the company
designs to selectively target and modulate the activity of specific
proteins implicated in various disease states. The company is
developing its most advanced SMNH product candidate, SB 9200, for
the treatment of viral diseases, including hepatitis B virus. SB
9200 has been designed to selectively activate within infected
cells the cellular proteins, retinoic acid-inducible gene 1, or
RIG-I, and nucleotide-binding oligomerization domain-containing
protein 2, or NOD2, which have been implicated in the body’s immune
response to viral infections. Spring Bank believes that SB 9200 may
play an important role in antiviral therapy by modulating the
body’s immune response through its mechanisms of action to fight
viral infections such as HBV.
Spring Bank Safe Harbor
Statement:
Any statements in this press release about Spring
Bank’s future expectations, plans and prospects, including
statements about Spring Bank’s financial prospects and future
operations and other statements containing the words "believes,"
"anticipates," "estimates," "expects," "intends," "plans,"
"predicts," "projects," "targets," "may," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including whether Spring Bank’s cash resources will be
sufficient to fund its continuing operations for the periods
anticipated; whether results obtained in clinical trials will be
indicative of results obtained in future clinical trials; whether
Spring Bank’s product candidates will advance through the clinical
trial process on a timely basis; whether the results of such trials
will warrant submission for approval from the United States Food
and Drug Administration or equivalent foreign regulatory agencies;
whether Spring Bank’s product candidates will receive approval from
regulatory agencies on a timely basis or at all; whether, if
product candidates obtain approval, they will be successfully
distributed and marketed; and other risks and uncertainties
identified under the heading "Risk Factors" included in the
Company’s effective Registration Statement on Form S-1 as filed
with the Securities and Exchange Commission (SEC) on December 16,
2016, and in other filings Spring Bank makes with the SEC from time
to time. In addition, the forward-looking statements included in
this press release represent Spring Bank’s views as of the date
hereof. Spring Bank anticipates that subsequent events and
developments will cause Spring Bank’s views to change. However,
while Spring Bank may elect to update these forward-looking
statements at some point in the future, Spring Bank specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing Spring Bank’s views as of
any date subsequent to the date hereof.
Jon Freve
Chief Financial Officer
Spring Bank Pharmaceuticals
(508) 473-5993
jfreve@springbankpharm.com
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Sep 2023 to Sep 2024